Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.52 |
| ▸ | BHMT | Q93088 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648478 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL75174 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL2263294 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL398726 | 1.00 | SLC7A5 (0.52) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL7411924 | 0.84 | SLC7A5 (0.46) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL14689821 | 0.83 | ALDH1A1 (0.38) | SLC7A5BHMTGABRPGABRDGABRA1 | |
| SCHEMBL24261803 | 0.83 | BHMT (0.40) | SLC7A5BHMTTDP1GABRPGABRD | |
| SCHEMBL5319867 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 | |
| SCHEMBL5319869 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 | |
| SCHEMBL10824295 | 0.83 | SLC7A5 (0.50) | SLC7A5BHMTKMT2ASLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | claimed |
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | claimed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | claimed |
| US-20220026398-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2022-01-27 | — | — | US | claimed |
| CN-113301893-A | Treatment of neurological disorders | 阿克里普斯一有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | claimed |
| EP-3638284-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2020-04-22 | — | — | EP | claimed |
| CN-102485902-B | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2014-08-13 | — | — | CN | claimed |
| CN-102485902-A | Method for producing daptomycin by fermentation | UNIV PEKING FOUNDER GROUP CO | 2012-06-06 | — | — | CN | claimed |
| WO-2002059322-A9 | COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN BIOSYNTHETIC GENE CLUSTER | CUBIST PHARMACEUTICLAS INC (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2002059322-A2 | COMPOSITIONS AND METHODS RELATING TO THE DAPTOMYCIN BIOSYNTHETIC GENE CLUSTER | CUBIST PHARMACEUTICLAS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| US-6310093-B1 | ADMINISTERING, IN AMOUNT EFFECTIVE TO REDUCE DAMAGE TO NEURONAL CELLS, COMPOUND WHICH SELECTIVELY INHIBITS EXTRACELLULAR GLUTAMINASE RELATIVE TO GLUTAMINASE PRESENT IN INTACT CELLS AND IS IMPERMEABLE TO INTACT CELL MEMBRANES | ELAN PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | claimed |
| WO-1999009825-A1 | METHOD OF PREVENTING NEURONAL DEATH | ELAN PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0010421-B1 | MIXTURE OF ANTIBIOTICS DESIGNATED BY A-21978, PROCESS FOR ITS PRODUCTION, THEIR PHARMACEUTICAL COMPOSITIONS AND PRODUCING MICROORGANISM | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | claimed |
| US-RE32455-E | A-21978 antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1987-07-07 | — | — | US | claimed |
| US-4331594-A | PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-05-25 | — | — | US | claimed |
| EP-0010421-A1 | Mixture of antibiotics designated by A-21978, process for its production, their pharmaceutical compositions and producing microorganism | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | SLC7A5 2179/4885BHMT 2607/4885TDP1 4233/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | SLC7A5 196/4885BHMT 3710/4885TDP1 4429/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | SLC7A5 37/4885BHMT 80/4885TDP1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.